SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Trickle Portfolio
An SI Board Since October 2000
Posts SubjectMarks Bans
1784 65 0
Emcee:  tuck Type:  Unmoderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1084You're welcome, and FWIW: siliconinvestor.com Cheers, Tucktuck-3/8/2002
1083Thanks, that's a sensational summary and feel. (eom)scaram(o)uche-3/8/2002
1082I see I already dispensed with DPII, and IVGN is improving its communications ontuck-3/8/2002
1081Tuck, thx for giving me a "direction" as what to look for in Shimadzu Crossy-3/7/2002
1080Crossy: Good link I posted on the NBSC board. I mentioned them as a possible hrichardred-3/7/2002
1079Crossy, I know Shimadzu makes some analytical equipment, mass specs, front end tuck-3/7/2002
1078to Tuck & all on this thread.. Opinion sought on SHIMADZU shimadzu.com SBU Crossy-3/6/2002
1077Tuck, thx alot for the AGNT update. That looks interesting - think it warrants aCrossy-3/6/2002
1076Hi Nigel, just a remark on the sidelines of the UK... OXIG.L (Oxford InstrumentsCrossy-3/6/2002
1075GeneProt and Zymark Reach Automation Technology Agreement for U.S. and Europe Nnigel bates-3/4/2002
1074IVGN has been an accident waiting to happen - 10% organic growth, and P/S exceeSpekulatius-3/3/2002
1073AGNT: update of BIO CEO and earnings CCs, with more color on the Jones Chromatogtuck-3/1/2002
1072>>SAN DIEGO, Feb 28 (Reuters) - Invitrogen Corp. (NasdaqNM:IVGN - news), atuck-2/28/2002
1071We don't know who won, but at least it's over. WRT IP litigation, this tuck-2/26/2002
1070DPII said that some pharmas had NanoKans "in their budgets" but they dtuck-2/25/2002
1069In the better late than never department, my take on EBIO's earnings releasetuck-2/24/2002
1068BDAL reports, and just misses Q4 revenue estimates (by $300K, close enough, realtuck-2/21/2002
1067Given the price action in QGENF over the last three days to the present, the Robtuck-2/21/2002
1066Trickle buys 100 QGENF @ $16.10, and 400 AGNT @ $2.35 both the current asks. Chtuck-2/20/2002
1065I was surprised to see QGENF slide so hard today, and both Trickle and its managtuck-2/19/2002
1064PCOP painting a rosy future for Accelrys in this report. About the only bioinfotuck-2/14/2002
1063>>PRINCETON, N.J., and OSS, Netherlands, Feb. 13 /PRNewswire-FirstCall/ --tuck-2/13/2002
1062AGNT reports: >>FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 12, 2002--Argotuck-2/12/2002
1061>>PRINCETON, N.J., Feb. 12 /PRNewswire-FirstCall/ -- Pharmacopeia, Inc. (Ntuck-2/12/2002
1060DPII hits guidance (edit: EBIO also hit estimates; with revenue being $100K betttuck-2/12/2002
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News